Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 15

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 15
---
     |            |     4,431 |     |             | -           |   |     |               |       4,431 |   |
| Net                                
 loss                               |     |                 |         - |     |        |         - |     |        |          - |     |        |          - |     |        |   - |     |        | - |     |            |         - |     |             | (572,211    | ) |     |               |    (572,211 | ) |
| Balance                            
 at February 13, 2024 (Predecessor) |     |                 | 5,155,703 |     | $      | 4,077,560 |     |        | 22,764,764 |     | $      | 38,023,784 |     |        | 292 |     | $      | - |     | $          | 1,036,557 |     | $           | (43,662,032 | ) |     | $             | (42,625,475 | ) |

<div align='center'>See accompanying notes to the condensed consolidated financial statements

Reflects a 1-for-100 reverse stock split effective January 8, 2025 and 1-for-20 reverse stock split effective June 13, 2025

4

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)</div>

|                                                                                |     | For the    
 Six Months 
 ended      
 June 30,   
 2025       |             |   |     | For the      
 Period from  
 February 14, 
 2024 through 
 June 30,     
 2024         |            |   |     | For the      
 Period from  
 January 1,   
 2024 through 
 February 13, 
 2024         |           |   |
|:-------------------------------------------------------------------------------|:----|:-----------|------------:|:--|:----|:-------------|-----------:|:--|:----|:-------------|----------:|:--|
|                                                                                |     | -Successor |             |   |     | -Successor   |            |   |     | -Predecessor |           |   |
| Cash flows from operating activities:                                          |     |            |             |   |     |              |            |   |     |              |           |   |